New horizons in allergy diagnostics and treatment

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 5, 2013, Pages 246-250

  Pawliczak, Rafał ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Allergy; Asthma; New treatments

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; COLECALCIFEROL; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; VITAMIN D; ANTIALLERGIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CROSS REACTION; FOOD ALLERGY; HUMAN; IMMUNOTHERAPY; MOLECULAR DIAGNOSIS; PHYSICIAN; POLLEN; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; RISK ASSESSMENT; SENSITIZATION; PRIMARY PREVENTION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINITIS, ALLERGIC, PERENNIAL; TREATMENT OUTCOME;

ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; HUMANS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, PERENNIAL; TREATMENT OUTCOME;

EID: 84880093315     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1732     Document Type: Review

References (46)

1. Samoliński B, Sybilski AJ, Raciborski F, et al. Prevalence of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. Otolaryngol Pol. 2009; 63: 324-330.
2. Settipane RA, Charnock DR. Epidemiology of rhinitis: allergic and nonallergic. Clin Allergy Immunol. 2007; 19: 23-34.
3. Venter C, Arshad SH. Epidemiology of food allergy. Pediatr Clin North Am. 2011; 58: 327-349, ix.
4. Kumar R. Epidemiology and risk factors for the development of food allergy. Pediatr Ann. 2008; 37: 552-558.
5. Sicherer SH, Leung D Y. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2011. J Allergy Clin Immunol. 2012; 129: 76-85.
6. Nermes M, Kantele JM, Atosuo TJ, et al. Interaction of orally administered Lactobacillus rhamnosus GG with skin and gut microbiota and humoral immunity in infants with atopic dermatitis. Clin Exp Allergy. 2011; 41: 370-377.
7. Torii S, Torii A, Itoh K, et al. Effects of oral administration of Lactobacillus acidophilus L-92 on the symptoms and serum markers of atopic dermatitis in children. Int Arch Allergy Immunol. 2011; 154: 236-245.
8. Grüber C, Wendt M, Sulser C, et al. Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy. Allergy. 2007; 62: 1270-1276.
9. Fölster-Holst R, Müller F, Schnopp N, et al. Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. Br J Dermatol. 2006; 155: 1256-1261.
10. Jensen M P, Meldrum S, Taylor AL, et al. Early probiotic supplementation for allergy prevention: long-term outcomes. J Allergy Clin Immunol. 2012; 130: 1209-1211.e5.
11. El-Qutob López D. New methods of prevention and treatment of allergic diseases. Recent Pat Inflamm Allergy Drug Discov. 2012; 6: 46-64.
12. Maslova E, Granström C, Hansen S, et al. Peanut and tree nut consumption during pregnancy and allergic disease in children - should mothers decrease their intake? Longitudinal evidence from the Danish National Birth Cohort. J Allergy Clin Immunol. 2012; 130: 724-732.
13. Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012; 129: 448-455, 455 e1-5.
14. Leonard SA, Sampson HA, Sicherer SH, et al. Dietary baked egg accelerates resolution of egg allergy in children. J Allergy Clin Immunol. 2012; 130: 473-480.e1.
15. Onell A, Hjälle L, Borres M P. Exploring the temporal development of childhood IgE profiles to allergen components. Clin Transl Allergy. 2012; 2: 24.
16. Alessandri C, Zennaro D, Scala E, et al. Ovomucoid (Gal d 1) specific IgE detected by microarray system predict tolerability to boiled hen's egg and an increased risk to progress to multiple environmental allergen sensitisation. Clin Exp Allergy. 2012; 42: 441-450.
17. Melioli G, Marcomini L, Agazzi A, et al. The IgE repertoire in children and adolescents resolved at component level: a cross-sectional study. Pediatr Allergy Immunol. 2012; 23: 433-440.
18. Hauser M, Asam C, Himly M, et al. Bet v 1-like pollen allergens of multiple Fagales species can sensitize atopic individuals. Clin Exp Allergy. 2011; 41: 1804-1814.
19. Scala E, Alessandri C, Palazzo P, et al. IgE recognition patterns of profilin, PR-10, and tropomyosin panallergens tested in 3,113 allergic patients by allergen microarray-based technology. PLoS One. 2011; 6: e24 912.
20. Gadermaier G, Harrer A, Girbl T, et al. Isoform identification and characterization of Art v 3, the lipid-transfer protein of mugwort pollen. Mol Immunol. 2009; 46: 1919-1924.
21. Hong X, Caruso D, Kumar R, et al. IgE, but not IgG4, antibodies to Ara h 2 distinguish peanut allergy from asymptomatic peanut sensitization. Allergy. 2012; 67: 1538-1546.
22. Asarnoj A, Nilsson C, Lidholm J, et al. Peanut component Ara h 8 sensitization and tolerance to peanut. J Allergy Clin Immunol. 2012; 130: 468-472.
23. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013; 368: 924-935.
24. Song CH, Stern S, Giruparajah M, et al. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2013; 110: 113-117.
25. Nam YH, Kim JH, Jin HJ, et al. Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy Asthma Immunol Res. 2012; 4: 357-361.
26. Metz M, Maurer M. Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol. 2012; 12: 406-411.
27. Rafi A, Do LT, Katz R, et al. Effects of omalizumab in patients with food allergy. Allergy Asthma Proc. 2010; 31: 76-83.
28. Noh G, Lee JH. Regulatory B cells and allergic diseases. Allergy Asthma Immunol Res. 2011; 3: 168-177.
29. Schafer T, Starkl P, Allard C, et al. A granular variant of CD63 is a regulator of repeated human mast cell degranulation. Allergy. 2010; 65: 1242-1255.
30. Chen KW, Blatt K, Thomas WR, et al. Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. J Allergy Clin Immunol. 2012; 130: 435-443.e4.
31. Bussieres L, Bordas-Le Floch V, Bulder I, et al. Recombinant fusion proteins assembling Der p 1 and Der p 2 allergens from Dermatophagoides pteronyssinus. Int Arch Allergy Immunol. 2010; 153: 141-151.
32. Vickery BP, Lin J, Kulis M, et al. Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens. J Allergy Clin Immunol. 2013; 131: 128-34.e1-3.
33. Schmitz N, Dietmeier K, Bauer M, et al. Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med. 2009; 206: 1941-1955.
34. Hakim A, Adcock IM, Usmani OS. Corticosteroid resistance and novel anti-inflammatory therapies in chronic obstructive pulmonary disease: current evidence and future direction. Drugs. 2012; 72: 1299-1312.
35. Page CP, Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol. 2012; 12: 275-286.
36. Shan WJ, Huang L, Zhou Q, et al. Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD. Bioorg Med Chem Lett. 2012; 22: 1523-1526.
37. Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol. 2012; 181: 8-18.
38. Petersen BC, Lukacs NW. IL-17A and IL-25: therapeutic targets for allergic and exacerbated asthmatic disease. Future Med Chem. 2012; 4: 833-836.
39. Mizutani N, Goshima H, Nabe T, Yoshino S. Complement C3a-induced IL-17 plays a critical role in an IgE-mediated late-phase asthmatic response and airway hyperresponsiveness via neutrophilic inflammation in mice. J Immunol. 2012; 188: 5694-5705.
40. Silverpil E, Lindén A. IL-17 in human asthma. Expert Rev Respir Med. 2012; 6: 173-186.
41. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev. 2010; 19: 46-54.
42. Antoniu SA, Cojocaru I. Pitrakinra for asthma. Expert Opin Biol Ther. 2010; 10: 1609-1615.
43. Slager RE, Hawkins GA, Ampleford EJ, et al. IL-4 receptor a polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist. J Allergy Clin Immunol. 2010; 126: 875-878.
44. Tse SM, Kelly HW, Litonjua AA, et al. Corticosteroid use and bone mineral accretion in children with asthma: effect modification by vitamin D. J Allergy Clin Immunol. 2012; 130: 53-60.e4.
45. 3 pretreatment enhances the efficacy of allergen immunotherapy in a mouse allergic asthma model. Chin Med J (Engl). 2010; 123: 3591-3596.
46. Majak P, Rychlik B, Stelmach I. The effect of oral steroids with and without vitamin D3 on early efficacy of immunotherapy in asthmatic children. Clin Exp Allergy. 2009; 39: 1830-1841.